Immunocore Holdings IMCR
NASDAQ IMCR
$36.13 -1.44 (-3.85%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immunocore Holdings (IMCR) Total Non-Current Liabilities (2019 - 2026)

Immunocore Holdings (IMCR) posted Total Non-Current Liabilities of $609.3 million for Q3 2025, little changed sequentially from $609.9 million in Q2 2025, and down 13.42% YoY from $703.8 million in Q3 2024.

Analysis

Immunocore Holdings (IMCR) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends

Immunocore Holdings has reported Total Non-Current Liabilities for 7 years, with the latest figure at $609.3 million in Q3 2025.

  • Quarterly Total Non-Current Liabilities fell 13.42% year-over-year to $609.3 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $609.3 million (down 13.42% YoY) and the FY2024 annual result came in at $648.8 million, up 185.58% from the prior year.
  • Total Non-Current Liabilities held at $609.3 million in Q3 2025 per IMCR's latest filing, from $609.9 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $703.8 million in Q3 2024 and troughed at $85.6 million in Q3 2022.
  • A 5-year average of $419.5 million and a median of $598.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities decreased 18.84% in 2021, then surged 647.38% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at $93.1 million in 2021, then declined by 7.16% to $86.4 million in 2022, then soared by 162.9% to $227.2 million in 2023, then surged by 185.58% to $648.8 million in 2024, then dropped by 6.08% to $609.3 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $609.3 million, $609.9 million, and $587.1 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 40.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 3.92 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 1.53 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.88 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 4.20 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.32 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 1.17 Bn
10 Immunocore Holdings 1.85 Bn 965.54 Mn 114.84 Mn 672.74 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 672.74 Mn
Dec 31, 2025 686.24 Mn
Sep 30, 2025 609.33 Mn
Jun 30, 2025 609.95 Mn
Mar 31, 2025 587.05 Mn
Dec 31, 2024 648.79 Mn
Sep 30, 2024 703.81 Mn
Jun 30, 2024 662.14 Mn
Mar 31, 2024 632.29 Mn
Dec 31, 2023 227.18 Mn
Jun 30, 2023 88.60 Mn
Dec 31, 2022 86.41 Mn
Sep 30, 2022 85.61 Mn
Dec 31, 2021 93.07 Mn
Dec 31, 2020 114.68 Mn
Dec 31, 2019 111.04 Mn